tradingkey.logo

Nuwellis Inc

NUWE
4.380USD
+0.530+13.77%
Market hours ETQuotes delayed by 15 min
5.98MMarket Cap
0.02P/E TTM

Nuwellis Inc

4.380
+0.530+13.77%

More Details of Nuwellis Inc Company

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

Nuwellis Inc Info

Ticker SymbolNUWE
Company nameNuwellis Inc
IPO dateFeb 16, 2012
CEOErb (John L)
Number of employees38
Security typeOrdinary Share
Fiscal year-endFeb 16
Address12988 Valley View Rd
CityEDEN PRAIRIE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55344
Phone19523454200
Websitehttps://www.nuwellis.com/
Ticker SymbolNUWE
IPO dateFeb 16, 2012
CEOErb (John L)

Company Executives of Nuwellis Inc

Name
Name/Position
Position
Shareholding
Change
Erb (John L)
Erb (John L)
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
803.00
+803.00%
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
3.00
+3.00%
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Mr. Michael (Mike) Mccormick
Mr. Michael (Mike) Mccormick
Lead Independent Director
Lead Independent Director
--
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Erb (John L)
Erb (John L)
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
803.00
+803.00%
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
3.00
+3.00%
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Mr. Michael (Mike) Mccormick
Mr. Michael (Mike) Mccormick
Lead Independent Director
Lead Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
5.41%
DRW Securities, LLC
2.14%
Bigger Capital Funds, LP
0.34%
Citi Investment Research (US)
0.13%
Tower Research Capital LLC
0.06%
Other
91.93%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
5.41%
DRW Securities, LLC
2.14%
Bigger Capital Funds, LP
0.34%
Citi Investment Research (US)
0.13%
Tower Research Capital LLC
0.06%
Other
91.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.41%
Investment Advisor
2.18%
Hedge Fund
0.40%
Research Firm
0.13%
Individual Investor
0.02%
Other
91.87%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
20
134.31K
8.11%
+91.72K
2025Q3
18
13.52K
2.03%
+10.09K
2025Q2
27
9.97K
1.46%
+7.11K
2025Q1
26
140.31K
3.15%
+23.64K
2024Q4
25
113.78K
2.60%
+73.44K
2024Q3
29
65.32K
2.68%
+45.76K
2024Q2
28
42.02K
3.15%
+30.15K
2024Q1
26
9.25K
4.91%
+1.97K
2023Q4
26
6.22K
6.75%
+3.61K
2023Q3
35
1.28K
4.82%
-1.76K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
35.89K
2.16%
+32.37K
+918.85%
Sep 30, 2025
DRW Securities, LLC
36.08K
2.18%
+36.08K
--
Sep 30, 2025
Bigger Capital Funds, LP
5.69K
0.34%
+5.69K
--
Jun 09, 2025
Citi Investment Research (US)
1.15K
0.13%
+1.15K
--
Sep 30, 2025
Tower Research Capital LLC
1.03K
0.06%
+898.00
+680.30%
Sep 30, 2025
UBS Financial Services, Inc.
2.86K
0.17%
+979.00
+52.10%
Sep 30, 2025
Erb (John L)
803.00
0.02%
+803.00
--
Jun 10, 2025
SBI Securities Co., Ltd.
63.00
0%
+2.00
+3.28%
Sep 30, 2025
The Vanguard Group, Inc.
31.00
0%
--
--
Nov 30, 2025
BofA Global Research (US)
5.00
0%
+4.00
+400.00%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Jul 02, 2025
Merger
42→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Dec 09, 2022
Merger
100→1
Date
Ex-dividend Date
Type
Ratio
Jul 02, 2025
Merger
42→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Jun 26, 2024
Merger
35→1
Dec 09, 2022
Merger
100→1
Dec 09, 2022
Merger
100→1
Dec 09, 2022
Merger
100→1
Dec 09, 2022
Merger
100→1
Oct 17, 2020
Merger
30→1
View more
KeyAI